PriceTargets.com logo

Galecto - GLTO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.67
  • Forecasted Upside: 489.23%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.98 As of 03/30/2023 01:00 AM ET
▲ +0.05 (2.59%)

This chart shows the closing price for GLTO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Galecto Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GLTO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GLTO

Analyst Price Target is $11.67
▲ +489.23% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Galecto in the last 3 months. The average price target is $11.67, with a high forecast of $16.00 and a low forecast of $6.00. The average price target represents a 489.23% upside from the last price of $1.98.

This chart shows the closing price for GLTO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Galecto. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/17/2023Cantor FitzgeraldInitiated CoverageOverweight$16.00Low
3/10/2023Credit Suisse GroupReiterated RatingOutperform$6.00Low
8/3/2022SVB LeerinkLower TargetOutperform$16.00 ➝ $13.00Low
8/6/2021Credit Suisse GroupLower TargetOutperform$12.00 ➝ $7.00Medium
3/16/2021Credit Suisse GroupLower TargetOutperform$29.00 ➝ $12.00High
3/16/2021SVB LeerinkLower TargetOutperform$27.00 ➝ $16.00High
11/23/2020SVB LeerinkInitiated CoverageOutperform$27.00High
11/23/2020Credit Suisse GroupInitiated CoverageOutperform$29.00High
11/23/2020Bank of AmericaInitiated CoverageBuyHigh
(Data available from 3/30/2018 forward)

News Sentiment Rating

0.07 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/31/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2023

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Galecto logo
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Read More

Today's Range

Now: $1.98
Low: $1.91
High: $2.03

50 Day Range

MA: $2.21
Low: $1.70
High: $2.86

52 Week Range

Now: $1.98
Low: $1.04
High: $2.95

Volume

47,850 shs

Average Volume

50,025 shs

Market Capitalization

$50.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79

Frequently Asked Questions

What sell-side analysts currently cover shares of Galecto?

The following sell-side analysts have issued reports on Galecto in the last twelve months: Cantor Fitzgerald, Credit Suisse Group AG, and SVB Leerink LLC.
View the latest analyst ratings for GLTO.

What is the current price target for Galecto?

3 Wall Street analysts have set twelve-month price targets for Galecto in the last year. Their average twelve-month price target is $11.67, suggesting a possible upside of 489.2%. Cantor Fitzgerald has the highest price target set, predicting GLTO will reach $16.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $6.00 for Galecto in the next year.
View the latest price targets for GLTO.

What is the current consensus analyst rating for Galecto?

Galecto currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GLTO will outperform the market and that investors should add to their positions of Galecto.
View the latest ratings for GLTO.

What other companies compete with Galecto?

Other companies that are similar to Galecto include Lantern Pharma, Bolt Biotherapeutics, NRx Pharmaceuticals, Atreca and Abeona Therapeutics. Learn More about companies similar to Galecto.

How do I contact Galecto's investor relations team?

Galecto's physical mailing address is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. The company's listed phone number is 45-7070-5210. The official website for Galecto is galecto.com. Learn More about contacing Galecto investor relations.